cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.7096105
title: CLM Standalone Simulation iztsector_pi_exper22a

description: See Readme_Simulations_c221028.pdf<br>
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5281/zenodo.7096104
title: CLM Standalone Simulation iztsector_pi_exper22a

description: See Readme_Simulations_c221028.pdf<br>
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5517/ccdc.csd.cc28tq72
title: CCDC 2110084: Experimental Crystal Structure Determination

description: Related Article: Anthony K. Edmonds, Catherine S. Oakes, Storm Hassell-Hart, Didier Bruyère, Graham J. Tizzard, Simon J. Coles, Robert Felix, Hannah J. Maple, Graham P. Marsh, John Spencer|2022|Org.Biomol.Chem.|20|4021|doi:10.1039/D2OB00609J
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc28382r
title: CCDC 2088503: Experimental Crystal Structure Determination

description: Related Article: Alessia Giordana, Emanuele Priola, Stefano Pantaleone, Luca Andreo, Leonardo Mortati, Paola Benzi, Lorenza Operti, Eliano Diana|2022|Dalton Trans.|51|5296|doi:10.1039/D2DT00201A
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2bf4fc
title: CCDC 2157582: Experimental Crystal Structure Determination

description: Related Article: Shuang He, Junjie Liu, Ge Yang, Zhengyang Bin, Jingsong You|2022|Materials Horizons|9|2818|doi:10.1039/D2MH00856D
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2bf4gd
title: CCDC 2157583: Experimental Crystal Structure Determination

description: Related Article: Shuang He, Junjie Liu, Ge Yang, Zhengyang Bin, Jingsong You|2022|Materials Horizons|9|2818|doi:10.1039/D2MH00856D
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2bzqy0
title: CCDC 2174493: Experimental Crystal Structure Determination

description: Related Article: Tongliang Zhou, Pengcheng Gao, Elwira Bisz, Błażej Dziuk, Roger Lalancette, Roman Szostak, Michal Szostak|2022|Cat.Sci.Tech.|12|6581|doi:10.1039/D2CY01136K
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2c0mkl
title: CCDC 2175349: Experimental Crystal Structure Determination

description: Related Article: Vladislav K. Lesnikov, Yulia V. Nelyubina, Alexey Yu. Sukhorukov|2022|New J.Chem.|46|20386|doi:10.1039/D2NJ03012H
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2c1knn
title: CCDC 2176251: Experimental Crystal Structure Determination

description: Related Article: Vladislav K. Lesnikov, Yulia V. Nelyubina, Alexey Yu. Sukhorukov|2022|New J.Chem.|46|20386|doi:10.1039/D2NJ03012H
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5517/ccdc.csd.cc2c1kpp
title: CCDC 2176252: Experimental Crystal Structure Determination

description: Related Article: Vladislav K. Lesnikov, Yulia V. Nelyubina, Alexey Yu. Sukhorukov|2022|New J.Chem.|46|20386|doi:10.1039/D2NJ03012H
description: An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
DOI: 10.5281/zenodo.7096097
title: CLM Standalone Simulation illsector_pi_exper22a

description: See Readme_Simulations_c221028.pdf<br>
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5281/zenodo.7096096
title: CLM Standalone Simulation illsector_pi_exper22a

description: See Readme_Simulations_c221028.pdf<br>
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5281/zenodo.7096089
title: CLM Standalone Simulation huasector_pi_exper22

description: See Readme_Simulations_c221028.pdf<br>
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5281/zenodo.7096088
title: CLM Standalone Simulation huasector_pi_exper22

description: See Readme_Simulations_c221028.pdf<br>
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.34740/kaggle/dsv/4428002
title: COVID Vaccination in World (updated daily)
DOI: 10.24378/exe.4224
title: Electricity market re-design in Great Britain: A proposed new design and lessons on implementation (Appendix 3 - Review of the 49 papers with proposals for electricity market reform)

description: Appendix 3 for the Doctoral thesis "Electricity market re-design in Great Britain: A proposed new design and lessons on implementation".
description: An excel spreadsheet detailing the review of 49 papers with proposals for electricity market reform
description: The thesis associated with this dataset is located in ORE at: http://hdl.handle.net/10871/131199
DOI: 10.5281/zenodo.7096085
title: CLM Standalone Simulation gilsector_pi_exper22a

description: See Readme_Simulations_c221028.pdf
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5281/zenodo.7096084
title: CLM Standalone Simulation gilsector_pi_exper22a

description: See Readme_Simulations_c221028.pdf
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5281/zenodo.7096016
title: CLM Standalone Simulation ccrsector_pi_exper22a

description: See Readme_Simulations_c221028.pdf
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5281/zenodo.7096015
title: CLM Standalone Simulation ccrsector_pi_exper22a

description: See Readme_Simulations_c221028.pdf
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.34808/1m9h-t218
title: Organochlorine pesticides and polichlorinated biphenyls concentrations in fresh snowfall or top layer of snow from Hornsund region, Svalbard, in the spring 2019

description: The dataset contains concentration of organochlorine persistent organic pollutants in snow samples collected from top layer of snow, which corresponded to fresh snowfall in most cases (except DS location, where these are 20 cm top layer sampled weekly). All snow samples have been collected within one month during spring 2019, in the vicinity of the Polish Polar Station, Svalbard. Snow sample location names ending in .1, .2 and .3 are local replicates of the same sample, i.e. snow sampled according to the same protocol, samples taken within the spacing of 1-3 m from one another. Sample locations H, R, F and DS refer to: Hans glacier, Revdalen (valley), Fugleberget slope, and the Environmental hut of the Polish Polar Station, respectively. All concentrations are given in ng/L of melted snow (water), i.e. ng/kg snow. Compound names are given at the top of columns denoting concentrations, for which an average of 3 analytical replicates and a standard deviation of those replicates is reported.The dataset is part of a project funded by SIOS (Svalbard Integrated Arctic Earth Observing System) Research Infrastructure Access Project 2018_0009 Sval-POPs: Spatial VAriabiLity: VALidation dataset on POPs concentrations in snow. The Polish Ministry for Science and Higher Education is thanked for the financial support to the SIOS programme, and the Polish Polar Station Hornsund crew from the 41st expedition of IG PAS, especially T. Biernacka and K. Ziemba, as well as A. Spolaor and C. Larose are acknowledged for valuable field assistance.
DOI: 10.5281/zenodo.7096038
title: CLM Standalone Simulation chisector_pi_exper22a

description: See Readme_Simulations_c221028.pdf
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.5281/zenodo.7096037
title: CLM Standalone Simulation chisector_pi_exper22a

description: See Readme_Simulations_c221028.pdf
description: The creation and archiving of these simulations were funded by the US National Science Foundation's Sedimentary Geology and Paleobiology Program (EAR-1849754).
DOI: 10.17903/fk2/swbjgl
title: Το Διαδίκτυο στην Κύπρο 2014 (Ελληνοκυπριακή και Τουρκοκυπριακή κοινότητα)

description: Πρόκειται για τον τέταρτο γύρο της έρευνας "Cyprus World Internet Project" που διεξήχθη τον Οκτώβριο-Δεκέμβριο του 2014 μέσω τηλεφωνικής συνέντευξης. Το μέγεθος του δείγματος είναι 2039 άτομα (1000 από την ελληνοκυπριακή κοινότητα και 1039 από την τουρκοκυπριακή κοινότητα). Συνεπώς, τα δεδομένα που συλλέγονται είναι αντιπροσωπευτικά του συνόλου του κυπριακού πληθυσμού. Επισημαίνεται ότι σε προηγούμενα κύματα της έρευνας (π.χ. 2008), εξετάζονταν μόνο οι απόψεις της ελληνοκυπριακής κοινότητας. Κύρια θέματα: Χρήση ΤΠΕ, ώρες πρόσβασης στο Διαδίκτυο, ψηφιακό χάσμα, εντυπώσεις στο Διαδίκτυο, χρήση μέσων, ηλεκτρονικές συναλλαγές, κοινωνική δικτύωση, ταυτότητα και κοινωνικές σχέσεις, συνολική αξιολόγηση του Διαδικτύου, Multitasking και Επικοινωνία, τοποθέτηση και πολιτική αποτελεσματικότητα, Ελευθερία λόγου και επιτήρησης, ενημέρωση και συζήτηση για το Κυπριακό πρόβλημα.
DOI: 10.3886/e182664
title: Data for: Historical gender discrimination does not explain comparative Western European development: evidence from Portugal, 1300-1900

description: Data for: Historical gender discrimination does not explain comparative Western European development: evidence from Portugal, 1300-1900.
DOI: 10.3886/e182664v1
title: Data for: Historical gender discrimination does not explain comparative Western European development: evidence from Portugal, 1300-1900

description: Data for: Historical gender discrimination does not explain comparative Western European development: evidence from Portugal, 1300-1900.
DOI: 10.34740/kaggle/ds/2109585
title: Steam Games Dataset
DOI: 10.6084/m9.figshare.21436638
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.6084/m9.figshare.21436638.v1
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.25549/usctheses-ouc11256057
title: Unknown
DOI: 10.5066/p9mikgor
title: Digital database of the previously published bedrock geologic map showing thickness of overlying Quaternary deposits, Grand Island quadrangle, Nebraska and Kansas

description: This digital data release contains geospatial data for the 1:250,000 scale geologic map of the Grand Island 1 degree by 2 degree quadrangle, Nebraska, originally published by Dreeszen and others (1973). The database includes line and polygon features depicting the extent of the Miocene Ogallala Formation and underlying Cretaceous rocks. The original map also included shaded patches indicating outcrop areas, and contour lines depicting the thickness of Quaternary deposits; these are not included in this database. The spatial data are accompanied by non-spatial tables that describe the sources of geologic information, a description of geologic map units, a glossary of terms, and a Data Dictionary that duplicates the Entity and Attribute information contained in the metadata file.
DOI: 10.25549/usctheses-c127-15547
title: Page 2
DOI: 10.6084/m9.figshare.21436647
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.6084/m9.figshare.21436647.v1
title: Supplementary Material for: Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment

description: Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial. Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without early PD were selected for cytokine array and genetic analyses. The identified factors were validated in the validated cohort (n = 60) and evaluated in patients treated with lenvatinib. Results: No significant differences were observed in the genetic alterations in circulating tumor DNA. Cytokine array data revealed that baseline MIG (CXCL9), ENA-78, and RANTES differed substantially between patients with and without early PD. Subsequent analysis in the validation cohort revealed that baseline CXCL9 was significantly lower in patients with early PD than that in patients without early PD, and the best cut-off value of serum CXCL9 to predict early PD was 333 pg/mL (sensitivity: 0.600, specificity: 0.923, AUC = 0.75). In patients with lower serum CXCL9 (&lt; 333 pg/mL), 35.3% (12/34) experienced early PD with atezolizumab plus bevacizumab, while progression-free survival (PFS) was significantly shorter relative to that in patients without (median PFS, 126 days vs 227 days; HR: 2.41, 95% CI: 1.22–4.80, p = 0.0084). While patients with objective response to lenvatinib had significantly lower CXCL9 levels compared with those of patients without. Conclusion: Baseline low serum CXCL9 (&lt; 333 pg/mL) levels may predict early PD in patients with unresectable HCC treated with atezolizumab plus bevacizumab.
DOI: 10.21227/04ta-v128
title: AI4Mobile Industrial Datasets: iV2V and iV2I+

description:  This dataset provides wireless measurements from two industrial testbeds: iV2V (industrial Vehicle-to-Vehicle) and iV2I+ (industrial Vehicular-to-Infrastructure plus sensor). iV2V covers sidelink communication scenarios between Automated Guided Vehicles (AGVs), while iV2I+ was conducted at an industrial setting where an autonomous cleaning robot is connected to a private cellular network. The datasets are labelled and pre-filtered for a fast on-boarding and applicability. The common measurement methodology to both datasets pursues an application to Machine Learning (ML) for tasks such as fingerprinting, line-of-sight detection, prediction of quality of service or link selection, among others.
DOI: 10.25549/usctheses-ouc11290561
title: Unknown
DOI: 10.25549/usctheses-ouc11290557
title: Unknown
DOI: 10.25549/usctheses-ouc11290592
title: Unknown
DOI: 10.25549/usctheses-ouc11290400
title: Unknown
DOI: 10.25549/usctheses-ouc11290589
title: Unknown
DOI: 10.25549/usctheses-ouc11290585
title: Unknown
DOI: 10.25549/usctheses-ouc11290325
title: Unknown
DOI: 10.25549/usctheses-ouc11256156
title: Unknown
DOI: 10.25549/usctheses-ouc11256151
title: Unknown
DOI: 10.25549/usctheses-ouc11256140
title: Unknown
DOI: 10.25549/usctheses-ouc11256133
title: Unknown
DOI: 10.25549/usctheses-ouc11256128
title: Unknown
DOI: 10.25549/usctheses-ouc11256125
title: Unknown
DOI: 10.25549/usctheses-ouc11256120
title: Unknown
DOI: 10.25549/usctheses-ouc11256119
title: Unknown
DOI: 10.25549/usctheses-ouc11256117
title: Unknown
DOI: 10.25549/usctheses-ouc11256115
title: Unknown
DOI: 10.25549/usctheses-ouc11256110
title: Unknown